Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Harvard Bioscience (HBIO) Work In Process (2016 - 2025)

Harvard Bioscience (HBIO) has disclosed Work In Process for 15 consecutive years, with $2.3 million as the latest value for Q3 2025.

  • On a quarterly basis, Work In Process fell 35.0% to $2.3 million in Q3 2025 year-over-year; TTM through Sep 2025 was $2.3 million, a 35.0% decrease, with the full-year FY2024 number at $2.8 million, down 34.24% from a year prior.
  • Work In Process was $2.3 million for Q3 2025 at Harvard Bioscience, up from $1.6 million in the prior quarter.
  • In the past five years, Work In Process ranged from a high of $4.6 million in Q3 2023 to a low of $1.6 million in Q2 2025.
  • A 5-year average of $3.5 million and a median of $3.5 million in 2021 define the central range for Work In Process.
  • Peak YoY movement for Work In Process: increased 20.7% in 2023, then tumbled 52.79% in 2025.
  • Harvard Bioscience's Work In Process stood at $3.4 million in 2021, then grew by 10.73% to $3.8 million in 2022, then grew by 10.91% to $4.2 million in 2023, then tumbled by 34.24% to $2.8 million in 2024, then fell by 18.08% to $2.3 million in 2025.
  • Per Business Quant, the three most recent readings for HBIO's Work In Process are $2.3 million (Q3 2025), $1.6 million (Q2 2025), and $3.0 million (Q1 2025).